Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 13;40(6):578-580.
doi: 10.1016/j.ccell.2022.04.015. Epub 2022 Apr 21.

COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge

Yotam Bronstein  1 , Roi Gat  1 , Shai Levi  1 , Yael C Cohen  2 , Efrat Luttwak  1 , Noam Benyamini  1 , Tamir Shragai  1 , Roy Vitkon  1 , Miriam Neaman  1 , Nili Eilaty  1 , Mor Levi  1 , Svetlana Trestman  1 , Chava Perry  2 , Yair Herishanu  2 , Irit Avivi  3
Affiliations

COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge

Yotam Bronstein et al. Cancer Cell. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of interests Y.H. reports honoraria from Janssen, AbbVie, Roche, Astra-Zeneca, and Medision, not related to this study. I.A. reports speaker’s bureau for Gilead, Novartis, AbbVie, and Janssen and served as a consultant for Janssen, MSD, AbbVie, Novartis, and Roche, not related to this study. The other authors declare no competing interests.

References

    1. Chatzikonstantinou T., Kapetanakis A., Scarfo L., Karakatsoulis G., Allsup D., Cabrero A.A., Andres M., Antic D., Baile M., Baliakas P., et al. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia. 2021;35:3444–3454. doi: 10.1038/s41375-021s4101450-8. - DOI - PMC - PubMed
    1. Christensen P.A., Olsen R.J., Long S.W., Snehal R., Davis J.J., Ojeda Saavedra M., Reppond K., Shyer M.N., Cambric J., Gadd R., et al. Signals of significantly increased vaccine Breakthrough, decreased hospitalization rates, and less severe disease in patients with Coronavirus disease 2019 Caused by the omicron variant of severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas. Am. J. Pathol. 2022;192:642–652. doi: 10.1016/j.ajpath.2022.01.007. - DOI - PMC - PubMed
    1. Herishanu Y., Avivi I., Aharon A., Shefer G., Levi S., Bronstein Y., Morales M., Ziv T., Shorer Arbel Y., Scarfo L., et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165–3173. doi: 10.1182/blood.2021011568. - DOI - PMC - PubMed
    1. Herishanu Y., Rahav G., Levi S., Braester A., Itchaki G., Bairey O., Dally N., Shvidel L., Ziv-Baran T., Polliack A., et al. on behalf of the Israeli CLL Study Group Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood. 2022;139:678–685. doi: 10.1182/blood.2021014085. - DOI - PMC - PubMed
    1. Mato A.R., Roeker L.E., Lamanna N., Allan J.N., Leslie L., Pagel J.M., Patel K., Osterborg A., Wojenski D., Kamdar M., et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136:1134–1143. doi: 10.1182/blood.2020006965. - DOI - PMC - PubMed

Supplementary concepts